Cancer in Serbia

IARC estimates 37,741 new cancer cases and 21,481 cancer deaths in Serbia in 2024; the commonest new cancers are colorectum, trachea, bronchus and lung and breast. This page is assembled automatically from OnCo's data: 75 trials with a site there, 1 institution and 1 person, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

37,741

all cancers

Deaths

21,481

all cancers

Incidence rate

266.5

per 100,000, age-standardised

Mortality rate

128.2

per 100,000, age-standardised

Cumulative risk

26.6%

of a cancer by age 74

Population

6,736,222

IARC, 2024

Built partly from other countries' data. IARC's method code for Serbia's incidence estimate is 3b: national mortality estimates applied to model-based mortality-to-incidence ratios (neighbouring country registry data). Read the figures as a regional estimate, not a count.

Most new cases

Site	New cases	Rate	OnCo page
Colorectum	5,533	35.6	Colorectal cancer
Trachea, bronchus and lung	5,494	35.6	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Breast	4,374	63.6	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Prostate	2,918	36.0	Prostate cancer
Bladder	2,129	13.3	Bladder & urothelial cancer
Pancreas	1,384	8.3	Pancreatic ductal adenocarcinoma
Corpus uteri	1,014	13.5	Endometrial cancer
Stomach	1,007	6.4	Gastric & gastro-oesophageal junction cancer
Cervix uteri	917	16.8	Cervical cancer
Melanoma of skin	899	6.8	Melanoma

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	5,076	31.4	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	2,764	15.3	Colorectal cancer
Breast	1,744	19.2	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Pancreas	1,289	7.4	Pancreatic ductal adenocarcinoma
Prostate	1,037	11.1	Prostate cancer
Stomach	824	5.0	Gastric & gastro-oesophageal junction cancer
Bladder	752	3.9	Bladder & urothelial cancer
Liver and intrahepatic bile ducts	715	4.0	Hepatocellular carcinoma
Brain, central nervous system	646	4.8	Glioma & glioblastoma
Leukaemia	488	3.2	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia

Incidence: method 3b, national mortality estimates applied to model-based mortality-to-incidence ratios (neighbouring country registry data).
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Serbia”, in Southern Europe (Europe), Very High HDI, upper middle income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

75 trials in OnCo · 21 recruiting overall

75 trials

Trial			Lead sponsor
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma NCT06697301	Phase 2/3	Recruiting	Eikon Therapeutics	127	2026-10-06
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07155187	Phase 2/3	Recruiting	AbbVie	117	2026-10-05
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult NCT06568939	Phase 2	Recruiting	AbbVie	82	2026-10-05
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus St NCT07155174	Phase 2	Recruiting	AbbVie	69	2026-10-02
A Platform Study in Non-Small Cell Lung Cancer (NSCLC) NCT06996782	Phase 1/2	Recruiting	AstraZeneca	103	2026-10-01
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma NCT05645107	Phase 3	Recruiting	Grifols Therapeutics LLC	62	2026-09-30
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC NCT04892173	Phase 3	Recruiting	Johnson & Johnson Enterprise Innovation Inc.	193	2026-09-25
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 NCT06767514	Phase 3	Recruiting	Summit Therapeutics	285	2026-09-18
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) NCT07625644	Phase 3	Recruiting	SystImmune Inc.	62	2026-09-17
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G NCT04613596	Phase 2/3	Recruiting	Mirati Therapeutics Inc.	770	2026-09-16
HERIZON-BTC-302 NCT06282575	Phase 3	Recruiting	Jazz Pharmaceuticals	185	2026-09-14
HARMONi-3 NCT05899608	Phase 3	Recruiting	Summit Therapeutics	260	2026-08-24
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy NCT05774951	Phase 3	Recruiting	AstraZeneca	709	2026-08-19
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC NCT05491525	Phase 2/3	Recruiting	Urovant Sciences GmbH	38	2026-06-15
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatme NCT06607458	Phase 2	Recruiting	Delcath Systems Inc.	14	2026-06-01
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma NCT06064877	Phase 3	Recruiting	AVEO Pharmaceuticals, Inc.	112	2026-04-09
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) NCT06428019	Phase 3	Recruiting	AbbVie	70	2026-04-09
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera NCT06093672	Phase 3	Recruiting	Italfarmaco	90	2026-03-25
SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer NCT07391813	Phase 1/2	Recruiting	SN BioScience	1	2026-03-09
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis NCT05201404	Phase 3	Recruiting	Can-Fite BioPharma	32	2025-04-29
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymp NCT04920617	Phase 2	Recruiting	ImmunoVaccine Technologies, Inc. (IMV Inc.)	50	2023-04-07
LITESPARK-012 NCT04736706	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	262	2026-10-02
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) NCT02227251	Phase 2	Active not recruiting	Karyopharm Therapeutics Inc	175	2026-10-01
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies NCT05329766	Phase 2	Active not recruiting	Arcus Biosciences, Inc.	43	2026-09-29
Volrustomig Priming Regimens Exploratory Phase II Platform Study NCT06448754	Phase 2	Active not recruiting	AstraZeneca	63	2026-09-29
HERIZON-GEA-01 NCT05152147	Phase 3	Active not recruiting	Jazz Pharmaceuticals	227	2026-09-24
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment- NCT04624204	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	187	2026-09-24
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study NCT02960022	Phase 2	Active not recruiting	Astellas Pharma Global Development, Inc.	234	2026-09-11
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell L NCT06687369	Phase 3	Active not recruiting	mAbxience Research S.L.	173	2026-09-10
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) NCT03178552	Phase 2/3	Active not recruiting	Hoffmann-La Roche	161	2026-09-03

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Serbia, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Serbia is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

1 institution

Oncology Institute of Vojvodina

1 person

People whose main affiliation in OnCo is an institution or company in Serbia.

Jasna Trifunovic

Approvals

OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Serbia is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Serbia's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Serbia, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines regulator, its approval routes and its decisions.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Serbia's own sources.

A deep dive for Serbia is ranked 49 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/rs.json; every country: /api/v1/countries.json.